Executive Summary
The Oral anti diabetes drug was valued at USD 25.6 Billion in the year 2018. Over the recent years, oral anti-diabetes drug has been witnessing considerable growth on the back of rising incidences of diabetes, growing geriatric population, growing government initiatives, and continuous research and development conducted by pharmaceutical manufacturers. In addition, growing sedentary lifestyle, presence of diabetes medicines in the Essential drug List of the nations and wide insurance coverage for diabetes drugs have contributed to the growth rate of Oral anti-diabetes drugs. These factors are anticipated to provide higher momentum to the market growth in the forecast period. However, preferred use of insulin over oral anti diabetes drugs and the complications associated with the drugs has been hindering the market growth.
Among all the types of oral anti-diabetes drugs that includes Biguanides, Sulfonylurease, DPP-4 inhibitor, SGL2 inhibitor and Thiazolidinedione, Biguanides holds the highest market share in the Oral Anti-diabetic drug Market owing to its proven benefits in the treatment of diabetes mellitus.
Among the regions, North America Oral Anti-diabetic drug Market will continue to be the largest market in the forecast period, majorly driven by favourable government reimbursement policies in addition to high healthcare awareness. Countries such as India, China, Brazil are a lucrative market for Oral Anti-diabetic drugs Market.
Scope of the Report
Global Oral Anti-Diabetes Drugs Market (Actual Period: 2014-2018, Forecast Period: 2019-2024)
Regional Oral Anti-Diabetes Drugs Market - North America, Europe, APAC, ROW (Actual Period: 2014-2018, Forecast Period: 2019-2024)
Country Analysis - U.S. Canada, U.K., Germany, France, Italy, India, Japan, China, Brazil (Actual Period: 2014-2018, Forecast Period: 2019-2024)
Other Report Highlights
Customization of the Report
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
The Oral anti diabetes drug was valued at USD 25.6 Billion in the year 2018. Over the recent years, oral anti-diabetes drug has been witnessing considerable growth on the back of rising incidences of diabetes, growing geriatric population, growing government initiatives, and continuous research and development conducted by pharmaceutical manufacturers. In addition, growing sedentary lifestyle, presence of diabetes medicines in the Essential drug List of the nations and wide insurance coverage for diabetes drugs have contributed to the growth rate of Oral anti-diabetes drugs. These factors are anticipated to provide higher momentum to the market growth in the forecast period. However, preferred use of insulin over oral anti diabetes drugs and the complications associated with the drugs has been hindering the market growth.
Among all the types of oral anti-diabetes drugs that includes Biguanides, Sulfonylurease, DPP-4 inhibitor, SGL2 inhibitor and Thiazolidinedione, Biguanides holds the highest market share in the Oral Anti-diabetic drug Market owing to its proven benefits in the treatment of diabetes mellitus.
Among the regions, North America Oral Anti-diabetic drug Market will continue to be the largest market in the forecast period, majorly driven by favourable government reimbursement policies in addition to high healthcare awareness. Countries such as India, China, Brazil are a lucrative market for Oral Anti-diabetic drugs Market.
Scope of the Report
Global Oral Anti-Diabetes Drugs Market (Actual Period: 2014-2018, Forecast Period: 2019-2024)
- Oral Anti-Diabetes Drugs Market – Size, Growth, Forecast
- Analysis by Type: Biguanides, Sulfonylurease, DPP-4 inhibitor, SGL2 inhibitor, Thiazolidinediones, Others
Regional Oral Anti-Diabetes Drugs Market - North America, Europe, APAC, ROW (Actual Period: 2014-2018, Forecast Period: 2019-2024)
- Oral Anti-Diabetes Drugs Market – Size, Growth, Forecast
- Analysis by Type: Biguanides, Sulfonylurease, DPP-4 inhibitor, SGL2 inhibitor, Thiazolidinediones, Others
Country Analysis - U.S. Canada, U.K., Germany, France, Italy, India, Japan, China, Brazil (Actual Period: 2014-2018, Forecast Period: 2019-2024)
- Oral Anti-Diabetes Drugs Market – Size, Growth, Forecast
- Analysis by Type: Biguanides, Sulfonylurease, DPP-4 inhibitor, SGL2 inhibitor, Thiazolidinediones, Others
Other Report Highlights
- Competitive Landscape – Sales, Segments, Market Share
- Leading Companies
- Non generic drug analysis
- Market Dynamics – Drivers and Restraints.
- Market Trends
- Porter Five Forces Analysis.
- SWOT Analysis.
- Company Analysis – Novartis, Pfizer, Sanofi, Merck & Co., AstraZeneca, Janssen Pharmaceutical, Boehringer Ingelheim, Eli Lilly, Takeda Pharmaceutical.
Customization of the Report
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
Table of Contents
1. Research Methodology2. Executive Summary3. Strategic Recommendations4. Oral Anti-Diabetic Drugs Market: Product Outlook
5. Global Oral Anti-Diabetic Drugs Market: Growth and Forecast
6. Global Oral Anti-Diabetic Drugs Market: Segment Analysis
7. Global Oral Anti-Diabetic Drugs Market: Regional Analysis
8. Global Anti-Diabetic Drugs Market: Competitive Landscape
9. Global Oral Anti-Diabetic Drugs Market Dynamics
10. Company Profiles
Companies Mentioned
- Novartis
- Pfizer
- Sanofi
- Merck & Co.
- AstraZeneca
- Janssen Pharmaceutical
- Boehringer Ingelheim
- Eli Lilly
- Takeda Pharmaceutical.
Methodology
LOADING...
